Day: December 14, 2021

Former CFO Amicably Departing the Company to Facilitate the Transition VANCOUVER, British Columbia, Dec. 14, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that Joe Ramelli has been appointed as Ketamine One’s new Chief Financial Officer (“CFO”) effective December 14, 2021, subject to the final acceptance of the NEO Exchange. Mr. Ramelli holds a Bachelor of Arts (with honours) in Business Economics from the University of California, Santa Barbara and has also attended the Director Education and Certification Program at the UCLA’s Anderson School of Management. Joe has nearly 30 years of experience in the public...

EDISON, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos”), a leading provider of safe, scalable, efficient, and sustainable zinc-based energy storage systems, today announced that Randall (“Randy”) B. Gonzales has been appointed Chief Financial Officer, to succeed Sagar Kurada who has announced his intention to resign, effective January 11, 2022. Eos CEO Joe Mastrangelo said, “Randy is a proven industrial CFO with a superior track record of delivering results and creating value. I’m excited to welcome Randy to Eos. He is a high-impact executive who brings a unique blend of capital allocation discipline, well-honed operating skills, and transformational leadership abilities. He will be a strong partner as we execute on our strategic plan to grow our business and deliver strong operating results,...

PALM BEACH, Fla., Dec. 14, 2021 (GLOBE NEWSWIRE) — Trump Media & Technology Group (‘TMTG’), today announced that it has entered into a wide-ranging technology and cloud services agreement with Rumble Inc. (‘Rumble’). As part of the partnership, Rumble will deliver video and streaming for TRUTH Social. TMTG and Rumble are also in exclusive negotiations for Rumble to provide infrastructure and video delivery services for TMTG’s Subscription Video On-Demand product, TMTG+. President Donald J. Trump, Chairman of TMTG, commented, “As part of our mission, TMTG continues to align with service providers who do not discriminate against political ideology. Therefore, I have selected the Rumble Cloud to serve as a critical backbone for TMTG infrastructure. TMTG has already launched Truth Social on the Rumble Cloud for invited guests...

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist. ILLUMINATE-206 Trial for the Treatment of Previously Treated Patients with Immunotherapy-Naïve Micro-Satellite Stable Colorectal Cancer (MSS-CRC)Preliminary data from the second 10 patients dosed in the safety cohort of ILLUMINATE-206, which involves tilsotolimod in combination with ipilimumab and nivolumab, showed a safety profile consistent with the first 10 patients in ILLUMINATE-206 and with prior studies. Eight patients had a post-baseline disease assessment evaluated per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1). Of those, one patient experienced Stable Disease (SD) with...

– Data demonstrate sotrovimab, developed by Vir in conjunction with GlaxoSmithKline, continues to retain in vitro neutralizing activity against all tested variants of concern, including Omicron – SAN FRANCISCO, Dec. 14, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant (B.1.1.529). A significant reduction in plasma neutralizing activity was observed against Omicron in sera from vaccinated and convalescent individuals. Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). Data demonstrate that sotrovimab and five other preclinical mAbs, developed by...

FORT WASHINGTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL) (tollbrothers.com), the nation’s leading builder of luxury homes, today announced that Derek T. Kan has joined the Company’s Board of Directors. Mr. Kan, age 43, currently leads business operations and strategy for Deliverr Inc., a startup focused on e-commerce fulfillment. Previously, he held a number of high-level positions in the Federal government, including as Deputy Director of the White House Office of Management and Budget and as Under Secretary at the U.S. Department of Transportation, where he served as a principal advisor to the Secretary and spearheaded initiatives involving technology and innovation in the transportation sector. He has also been announced as a nominee to serve on the bipartisan United States Postal Service Board of...

STAMFORD, Conn., Dec. 14, 2021 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (Nasdaq: EGLE) (“Eagle Bulk”, “Eagle”, or the “Company”), one of the world’s largest owner-operators within the Supramax/Ultramax dry bulk segment, today announced that the Company has signed a Partner Agreement with the Mærsk Mc-Kinney Møller Center for Zero Carbon Shipping (the “Center”), formalizing Eagle as a Mission Partner to the independent not-for-profit research and development center. As one of the largest owner-operators within the midsize drybulk segment, Eagle has resources, assets, and capabilities relevant to the Center’s projects. Through this collaboration, Eagle will provide support to the Center’s work and commit to the Center’s mission and vision of building a significant cross-disciplinary driving force in the decarbonization of the...

Responding to the rapidly evolving SARS-CoV-2, emerging variants and changing treatment landscape, Atea is updating the development strategy for AT-527 In addition to monotherapy evaluation, expanding development program to maximize AT-527’s profile for potential use in combination therapy to meet the current and future needs of COVID-19 as it transitions to endemic AT-527’s differentiated mechanism of action with dual targets, including chain termination (RdRp) and NiRAN inhibition, may potentially provide a high barrier to resistance with broad antiviral coverage to coronaviruses and variants making its profile well suited for monotherapy and combination use Initiating preclinical in vitro combination studies of AT-527 and other compounds with different mechanisms of action to evaluate additive and synergistic benefits BOSTON, Dec. ...